In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma

Pediatric Surgery International

Volumn 28, Issue 6, 2012, Pages 579-589

  Dewerth, Alexander ^a   Wonner, Timo ^a   Lieber, Justus ^a   Ellerkamp, Verena ^a   Warmann, Steven W ^a   Fuchs, Jörg ^a   Armeanu Ebinger, Sorin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Aurora Kinase A; Hepatoblastoma; Histone deacetylation; Kinase; Met; Multidrug resistance; Wee kinase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AURORA KINASE INHIBITOR; CASPASE 3; CDDP; CISPLATIN; HISTONE H3; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; TOZASERTIB; UNCLASSIFIED DRUG; VORINOSTAT; WEE1 INHIBITOR II;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CULTURE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; HEPATOBLASTOMA; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; SPHEROID CELL; TUMOR CELL; TUMOR CELL LINE; WESTERN BLOTTING;

DRUG SCREENING ASSAYS, ANTITUMOR; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84863980809     PISSN: 01790358     EISSN: 14379813     Source Type: Journal    
DOI: 10.1007/s00383-012-3086-6     Document Type: Article

References (56)

1. Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P et al (2000) Pretreatment prognostic factors for children with hepatoblastoma-results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36(11): 1418-1425
2. Stiller CA, Parkin DM (1996) Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 52(4):682-703
3. Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, Czaud-erna P et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28(15):2584-2590
4. Oue T, Yoneda A, Uehara S, Yamanaka H, Fukuzawa M (2009) Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J Pediatr Surg 44(2):377-380
5. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J (2002) The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer 95(8):1795-1801
6. Sawyers C (2004) Targeted cancer therapy. Nature 432(7015): 294-297
7. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14(6):1639-1648
8. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S et al (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91(13):1160-1162
9. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F et al (1998) Multinuclearity and increased ploidy caused by over-expression of the aurora-and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 58(21):4811-4816
10. Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5(1):1-10
11. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T et al (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10(3):262-267
12. McGowan CH, Russell P (1993) Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 12(1):75-85
13. O'Connell MJ, Raleigh JM, Verkade HM, Nurse P (1997) Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 16(3):545-554
14. De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Wurdinger T (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 17(13):4200-4207
15. Clayton AL, Hazzalin CA, Mahadevan LC (2006) Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 23(3):289-296
16. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ et al (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92(12):1300-1304
17. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59(2):177-189
18. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14(12):1497-1511
19. Rikiishi H (2011) Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011:830260
20. Rosato RR, Almenara JA, Dai Y, Grant S (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2(12):1273-1284
21. Doi I (1976) Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67(1):1-10
22. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, Von SD (1996) Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74(4): 809-818
23. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S (2011) Development of a drug resistance model for hepatoblastoma. Int J Oncol 38(2):447-454
24. Lieber J, Ellerkamp V, Wenz J, Kirchner B, Warmann SW, Fuchs J et al (2012) Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells. Pediatr Surg Int 28(2):149-159
25. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S (2012) Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1(nu) mice. Liver Int 32(4):574-581
26. Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplification of aurora-A in hepatocellular carcinoma. Clin Cancer Res 10(6):2065-2071
27. Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K et al (2003) Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37(3):534-543
28. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM (2001) Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153(5):1023-1034
29. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S (2007) Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of I kappa B alpha. Cancer Res 67(4): 1689-1695
30. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J et al (2008) Co-treatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 14(19):6106-6115
31. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60(18):5165-5170
32. Ma PC, Maulik G, Christensen J, Salgia R (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22(4):309-325
33. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A et al (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342(6248):440-443
34. Peruzzi B, Bottaro DP (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12(12):3657-3660
35. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25(4): 862-866
36. Hou J, Dong J, Sun L, Geng L, Wang J, Zheng J et al (2011) Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med 9:64
37. Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, Sugawara Y et al (2011) Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends 5(2):52-56
38. Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK et al (2011) Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene 30(9):1127-1134
39. Von SD, Faundez A, Teichmann B, Birnbaum T, Koch A, Hecker H et al (2000) Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepa-toblastoma. Int J Cancer 85(2):151-159
40. Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A et al (2009) Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE 4(4):e5120
41. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H et al (2002) Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian aurora kinases. Mol Cell Biol 22(3):874-885
42. Hsu JY, Sun ZW, Li X, Reuben M, Tatchell K, Bishop DK et al (2000) Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102(3):279-291
43. Warmann SW, Frank H, Heitmann H, Ruck P, Herberts T, Seitz G et al (2008) Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 144(1):43-48
44. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI (2006) The Aurora kinase inhibitor VX-680 induces endoredu-plication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66(15):7668-7677
45. El-Sheikh A, Fan R, Birks D, Donson A, Foreman NK, Vibhakar R (2010) Inhibition of Aurora Kinase A enhances chemosensi-tivity of medulloblastoma cell lines. Pediatr Blood Cancer 55(1):35-41
46. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265-7279
47. Wang X, Wong SC, Pan J, Tsao SW, Fung KH, Kwong DL et al (1998) Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res 58(22):5019-5022
48. Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM, Allis CD (2000) Synergistic coupling of histone H3 phosphory-lation and acetylation in response to epidermal growth factor stimulation. Mol Cell 5(6):905-915
49. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J et al (2008) Co-treatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 14(19):6106-6115
50. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD (2009) DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2:67
51. Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L et al (2006) PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 12(13):4080-4089
52. Arts J, De SS, Van EK (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10(22):2343-2350
53. Shitikova Z, Aksenov ND, Pospelov VA, Pospelov TV (2011) Cell senescence induced by histone deacetylase inhibitor sodium butyrate in rodent transformed cells resistant to apoptosis. Tsitologiia 53(3):277-284
54. Workman JL, Kingston RE (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67:545-579
55. Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH et al (2010) VX680/MK-0457, a potent and selective aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2(3):296-308
56. Desoize B, Gimonet D, Jardiller JC (1998) Cell culture as spheroids: an approach to multicellular resistance. Anticancer Res 18((6A)):4147-4158